TY - JOUR
T1 - Absent estrogen receptor and increased recurrence rate in breast cancer
AU - Knight, W.
AU - Livingston, R. B.
AU - Gregory, E. J.
AU - McGuire, W. L.
PY - 1977
Y1 - 1977
N2 - Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17%): 11/34 ER- and 8/79 ER+ pts., (32 vs 10%, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34%); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42%); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20%). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17%) as in Stage II, ER+ pts. (5/33 or 15%). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.
AB - Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17%): 11/34 ER- and 8/79 ER+ pts., (32 vs 10%, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34%); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42%); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20%). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17%) as in Stage II, ER+ pts. (5/33 or 15%). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.
UR - http://www.scopus.com/inward/record.url?scp=0017694717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017694717&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0017694717
VL - Vol. 18
SP - No. C-19
JO - Proceedings of the American Association for Cancer Research
JF - Proceedings of the American Association for Cancer Research
ER -